The apps, based on Apple's ResearchKit platform, will offer some iPhone owners the chance to get their DNA tested, many of them for the first time.
It's not really the same thing as 23andMe's original offering which screened for 254 diseases, but it's an important step in the right direction.
The money will be used to advance the company's genome-scale sequencing and interpretation services for inherited genetic disease and cancer.
The device and the app connect the smartphone to a server at UCLA, which rapidly measures the lengths of the individual DNA molecules.
The Series A1 funding round was led by UK-based Eurovestech, with participation from Peak Ventures, and a number of angel investors.
The device processes specific data retrieved from breath and analyzes that to graphically produce user friendly information on an accompanying smartphone app.
The company's mail-order DNA kits provide customers with an overview of their genetic ancestry, and risk assessments for certain diseases based on genetic data.
The company plans to use the new funds to keep working on its DNA-printing technology, and to start development of its own incubator.
Pathway Genomics is aiming to revolutionize the health and wellness industry by leveraging the natural language processing and cognitive capabilities of Watson.
The platform offers storing of a whole genome sequence for $25 per year, while a million API calls to work on the data costs just $1.